Marine bacterial extracts as a new rich source of drugs against Alzheimer’s disease
Open Access
- 5 August 2019
- journal article
- research article
- Published by Wiley in Journal of Neurochemistry
- Vol. 152 (4) , 493-508
Abstract
Alzheimer's disease (AD) is a prevalent, progressive and irreversible, neurodegenerative disease with no disease modifying treatment yet available. The projected burden of AD on our healthcare system is immense and thus there is an immediate need for new drugs that prevent or attenuate AD symptoms. While most efforts in the field are directed at treatments that reduce amyloid or tau burden in the brain, we have taken an alternate approach – a model based on reducing AD‐associated neuronal cell cycle events. Using this model, we have screened a largely unexplored source of compounds with therapeutic potential – the natural products created by diverse strains of marine bacteria. Two hundred and twenty‐five bacterial extracts from different strains were tested for both toxicity and neuroprotective properties by crystal violet and In‐cell Western – first in HT22 cells and then in mouse primary neuronal cultures. Based on these screens, we have identified several promising leads, and here we focus on the most promising of these. We found that we could directly assay even a crude bacterial extract in our E16 mouse cortical neuronal cultures and screen for activities that prevent cell cycle reentry and preserve synaptic structure. Preliminary tests in 1‐month‐old animals from a mouse model of Ataxia telangiectasia, showed that blockage of cell cycle‐related neuronal death could also be successful in vivo. This adds an important extension to our in vitro studies. These findings showcase a new effective and efficient assay system and validate the use of marine natural compounds as a novel source for new drugs to fight Alzheimer’s disease. image Cover Image for this issue: doi: 10.1111/jnc.14733.Keywords
This publication has 55 references indexed in Scilit:
- How to calculate sample size in animal studies?Journal of Pharmacology and Pharmacotherapeutics, 2013
- Novel venom peptides from the cone snail Conus pulicarius discovered through next-generation sequencing of its venom duct transcriptomeMarine Genomics, 2012
- Reimagining Alzheimer's Disease—An Age-Based HypothesisJournal of Neuroscience, 2010
- The Neuronal Expression of MYC Causes a Neurodegenerative Phenotype in a Novel Transgenic MouseThe American Journal of Pathology, 2009
- Cell cycle re-entry mediated neurodegeneration and its treatment role in the pathogenesis of Alzheimer's diseaseNeurochemistry International, 2009
- Aβ Oligomers Induce Neuronal Cell Cycle Events in Alzheimer's DiseaseJournal of Neuroscience, 2008
- The pRb/E2F cell-cycle pathway mediates cell death in Parkinson's diseaseProceedings of the National Academy of Sciences, 2007
- Cell division in the CNS: Protective response or lethal event in post-mitotic neurons?Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2006
- Molecular interaction of δ‐conotoxins with voltage‐gated sodium channelsFEBS Letters, 2005
- E2F1 Mediates Death of B-amyloid-treated Cortical Neurons in a Manner Independent of p53 and Dependent on Bax and Caspase 3Journal of Biological Chemistry, 2000